Skip to main content
. Author manuscript; available in PMC: 2011 Aug 16.
Published in final edited form as: J Acquir Immune Defic Syndr. 2008 May 1;48(1):44–52. doi: 10.1097/QAI.0b013e31816d9ba1

Table 3.

Proportion of HIV-infected and control men on lipid lowering therapy

HIV+ Control P-value
Any lipid lowering therapy 13.8% 1.4% <.0001
 Statin 8.9% 0.7% 0.0003
 Fibrate 6.8% 0.0% 0.0004
 Other Hypolipidemic 0.0% 0.7% 0.27

Note: analysis is age-restricted and OI-excluded.